Skip to main content
. 2020 Jun 2;105(9):3025–3035. doi: 10.1210/clinem/dgaa321

Figure 2.

Figure 2.

Risk of CV outcomes in the placebo group by achievement of CV risk factor goals at baseline: HbA1c <7.5%; LDL cholesterol <100 mg/dL or statin use; SBP <140 mmHg and DBP <90 mmHg; use of ACE inhibitor or ARB; normoalbuminuria; aspirin use; and/or nonsmoking. Cox regression analysis in patients treated with ≥1 dose of the study drug. Data on attainment of CV risk factor goals at baseline were unavailable for 85 patients (66 empagliflozin and 19 placebo). 3P-MACE indicates 3-point major adverse CV events (CV death, nonfatal myocardial infarction, or nonfatal stroke). Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; CV, cardiovascular; DBP, diastolic blood pressure; HbA1c, glycated hemoglobin; HHF, hospitalization for heart failure; HR, hazard ratio; LDL, low-density lipoprotein; SBP, systolic blood pressure. *Excludes fatal stroke.